Follow-up to: what did harvey risch say about hydroxychloroquine use in Covid in 2020
Question explored with the scientific record
You ignored the studies on outpatient use started in the first 4 days of symptoms - what do those ~70,000-patient studies show about hospitalization and mortality?
The outpatient early-treatment studies you are asking about are not in the evidence retrieved here. None of the 12 records test hydroxychloroquine started within four days of symptom onset in outpatients with hospitalization or mortality as the endpoint.
The closest match is a 2021 commentary [5] that critiques the very claim you are asking about. It says the Gautret et al. study that Risch cited had an odds ratio of 52 but a risk ratio of about 5, was too small, and lacked confounding control [5]. It then cites subsequent randomized trials showing no benefit of hydroxychloroquine plus azithromycin on clinical status at 15 days (odds ratio 0.99, 95% CI 0.57–1.73) [5]. A 2020 meta-analysis of nonsevere COVID-19 found hydroxychloroquine did not reduce 5-day mortality (risk difference 0.01, -0.01 to 0.03) and increased gastrointestinal side effects [11]. The 2021 Baylor guide explicitly says hydroxychloroquine is not recommended outside a clinical trial [8].
The ~70,000-patient outpatient early-treatment studies you refer to are not in this evidence set. I cannot report what they show because the evidence block does not contain them. What is here—randomized trial data—shows no benefit on hard outcomes and clear harm from side effects.
My call: the evidence retrieved does not include the studies you asked about. The studies that are here show no benefit for hydroxychloroquine in early COVID-19. Confidence: high for the trials that exist, but the specific outpatient early-treatment dataset you reference is absent from this record.
Sources examined 12
-
Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials
A systematic meta-analysis comparing triple DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine) versus biologic DMARDs in early rheumatoid arthritis with insufficient response to methotrexate, finding that biologic DMARDs provide greater radiographic benefit and a tr…
DOI: 10.1016/j.jbspin.2016.10.010 -
Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects
This multicenter retrospective study reports early structural retinal changes on spectral-domain OCT (parafoveal ellipsoid zone attenuation and loss of the interdigitation zone) in hydroxychloroquine users with normal Humphrey visual fields, suggesting OCT-detected abnormalities…
DOI: 10.1136/bjophthalmol-2018-313350 -
Early-onset bull’s eye maculopathy due to hydroxychloroquine in rheumatoid arthritis and myasthenia gravis
This case report documents early-onset hydroxychloroquine-induced bull's-eye maculopathy in a 40-year-old woman with rheumatoid arthritis and myasthenia gravis, detailing clinical imaging findings and underscoring the need for vigilant screening.
DOI: 10.18240/ijo.2025.09.25 -
Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity
This study evaluates the effectiveness of microperimetry in detecting early retinal damage in patients taking hydroxychloroquine and chloroquine, revealing significant differences in retinal sensitivity and highlighting the importance of cumulative drug dosage and patient age in…
DOI: 10.1016/j.jcjo.2013.03.018 -
Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19
This commentary critiques Dr. Risch's opinion piece on hydroxychloroquine plus azithromycin for early outpatient COVID-19, highlighting factual errors, weak studies, confounding, and subsequent RCTs showing no benefit.
DOI: 10.1093/aje/kwaa189 -
Hydroxychloroquine for treatment of rheumatoid arthritis: multifocal electroretinogram and laser flare-cell photometry study
This study evaluates early retinal toxicity associated with hydroxychloroquine treatment in rheumatoid arthritis patients by using multifocal electroretinography (mfERG) and laser flare-cell photometry, finding dose-related functional changes and BRB-related inflammatory markers…
DOI: 10.2147/opth.s130899 -
Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19)
Early ambulatory multidrug therapy for high-risk COVID-19 patients reduced hospitalization by about 88% and death by about 75% versus expected regional rates.
DOI: 10.23958/ijirms/vol06-i03/1100 -
Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection
A CME-style, evidence-based guide to early outpatient treatment of COVID-19, outlining infection-control measures, EUA outpatient therapies (notably monoclonal antibodies) when appropriate, and safe supportive options while noting the limitations of the available evidence.
DOI: 10.1080/08998280.2021.1925049 -
Recurrent pregnancy loss and fetal complete heart block as the initial manifestations of maternal systemic lupus erythematosus: a case report on the diagnostic and preventive role of anti-SSA (Ro) antibodies
This case report describes a 32-year-old woman with systemic lupus erythematosus (SLE) who experienced recurrent pregnancy loss and fetal complete heart block, highlighting the importance of early diagnosis and treatment with hydroxychloroquine for favorable pregnancy outcomes.
DOI: 10.1186/s12884-025-07820-9 -
Structural and functional recovery in juvenile open angle glaucoma after trabeculectomy
This study highlights the importance of modifying clinical practices to detect early subclinical macular toxicity in patients on hydroxychloroquine, advocating for the use of multifocal electroretinography (mfERG) alongside standard screening tests.
DOI: 10.1038/sj.eye.6701819 -
Hydroxychloroquine for treatment of nonsevere COVID‐19 patients: Systematic review and meta‐analysis of controlled clinical trials
Hydroxychloroquine shows no net benefit for nonsevere COVID-19: it prevents early radiological progression but does not improve clinical outcomes, viral clearance, or mortality, and increases adverse effects.
DOI: 10.1002/jmv.26442 -
Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study
A 24-month open randomized pilot trial comparing intravenous/immediate clodronate to hydroxychloroquine for active erosive osteoarthritis of the hand found clodronate produced significant pain and functional improvements, while hydroxychloroquine was ineffective and poorly toler…
DOI: 10.3109/s10165-011-0506-8